Related Experiment Video
Updated: Jul 19, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Adriamycin-induced oxidative mitochondrial cardiotoxicity
1Toxicology Graduate Program, Medical School, University of Minnesota, Duluth, Minnesota 55812, USA.
Abstract:
The anticancer agent Adriamycin (ADR) has long been recognized to induce a dose-limiting cardiotoxicity. Numerous studies have attempted to characterize and elucidate the mechanism(s) behind its cardiotoxic effect. Despite a wealth of data covering a wide-range of effects mediated by the drug, the definitive mechanism remains a matter of debate. However, there is consensus that this toxicity is related to the induction of reactive oxygen species (ROS). Induction of ROS in the heart by ADR occurs via redox cycling of the drug at complex I of the electron transport chain. Many studies support the theory that mitochondria are a primary target of ADR-induced oxidative stress, both acutely and long-term. This review focuses on the effects of ADR redox cycling on the mitochondrion, which support the hypothesis that these organelles are indeed a major factor in ADR cardiotoxicity. This review has been constructed with particular emphasis on studies utilizing cardiac models with clinically relevant doses or concentrations of ADR in the hope of advancing our understanding of the mechanisms of ADR toxicity. This compilation of current data may reveal valuable insights for the development of therapeutic strategies better tailored to minimizing the dose-limiting effect of ADR.
Insights
Adriamycin (ADR) causes heart damage through reactive oxygen species (ROS) generated by its redox cycling. Mitochondria are key targets, contributing significantly to ADR cardiotoxicity.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Adriamycin (ADR) is an effective anticancer drug but causes dose-limiting cardiotoxicity.
- The precise mechanisms of ADR-induced cardiotoxicity are debated, but reactive oxygen species (ROS) are implicated.
- Mitochondria are considered a primary target for ADR's oxidative stress effects.
Purpose of the Study:
- To review the effects of ADR redox cycling on mitochondria.
- To support the hypothesis that mitochondria play a major role in ADR cardiotoxicity.
- To advance understanding of ADR toxicity mechanisms using clinically relevant cardiac models.
Main Methods:
- Review of existing literature on Adriamycin (ADR) cardiotoxicity.
- Focus on studies investigating ADR's effects on mitochondrial function.
- Emphasis on studies using cardiac models with clinically relevant ADR doses.
Main Results:
- ADR redox cycling induces reactive oxygen species (ROS) in the heart.
- Mitochondria are significantly affected by ADR-induced oxidative stress.
- Evidence supports mitochondria as a major contributor to ADR cardiotoxicity.
Conclusions:
- Mitochondrial dysfunction is a key mechanism in Adriamycin (ADR) cardiotoxicity.
- Understanding these mechanisms can guide the development of strategies to mitigate ADR's cardiotoxic effects.
- Further research using relevant models is crucial for therapeutic advancements.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Drug Toxicity: Risk factors
Cellular Injury IV: Necrosis
Heart Failure Drugs: Inotropic Agents

